Editas Medicine (EDIT) Reports Q3 Loss of $0.66
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Editas Medicine (EDIT), Celgene Corp. (CELG) Update Collaboration Agreement to Develop/Commercialize Autologous & Allogeneic T Cell Medicines
November 12, 2019 7:13 AM ESTEditas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced an amended collaboration with Celgene Corporation (NASDAQ: CELG) under which the parties may research, develop, and commercialize autologous and... More
